SC 13G: Chemomab Therapeutics Ltd.
Ticker: CMMB · Form: SC 13G · Filed: Aug 20, 2024 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | SC 13G |
| Filed Date | Aug 20, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Chemomab Therapeutics Ltd..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Chemomab Therapeutics LTD. (ticker: CMMB) to the SEC on Aug 20, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
How long is this filing?
Chemomab Therapeutics LTD.'s SC 13G filing is 5 pages with approximately 1,438 words. Estimated reading time is 6 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,438 words · 6 min read · ~5 pages · Grade level 12.5 · Accepted 2024-08-20 14:36:44
Filing Documents
- zk2431899.htm (SC 13G) — 71KB
- exhibit_1.htm (EX-99) — 5KB
- 0001178913-24-002709.txt ( ) — 79KB
(a)
Item 1. (a) Name of Issuer : Chemomab Therapeutics Ltd. (b) Address of Issuer's Principal Executive Offices : Kiryat Atidim, Building 7, Tel Aviv 6158002, Israel
(a)
Item 2. (a) Name of Person Filing : Sphera Funds Management Ltd. Sphera Global Healthcare GP Ltd. Sphera Global Healthcare Management LP (b) Address of Principal Business Office : Sphera Funds Management Ltd. – 4 Itzak Sade, Building A, 29 th Floor, Tel Aviv 6777504, Israel Sphera Global Healthcare GP Ltd. – 4 Itzak Sade, Building A, 29 th Floor, Tel Aviv 6777504, Israel Sphera Global Healthcare Management LP – 4 Itzak Sade, Building A, 29 th Floor, Tel Aviv 6777504, Israel (c) Citizenship : Sphera Funds Management Ltd. – Israel Sphera Global Healthcare GP Ltd. – Israel Sphera Global Healthcare Management LP – Israel (d) Title of Class of Securities : American Depository Shares, each of which represents twenty ordinary shares, no par value (e) CUSIP Number : 16385C104 Item 3 . Not applicable. 5 Item 4 . (a) Amount beneficially owned : See row 9 of cover page of each reporting person. The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows: 1,214,575 ADSs, representing a total of 6.56% of the total ADSs outstanding, are held directly by Sphera Biotech Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the " Management Company "). The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd. This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 19